Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908101 · ClinicalTrials.gov registry record · Phase 2
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT01908101 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 86 participants.
The verdict
NCT01908101, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2014-01-08 |
| Est. Completion | 2019-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908101
The ClinicalTrials.gov registry entry for NCT01908101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01908101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908101 about?
NCT01908101 is a clinical study titled "Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer". This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the ...
What is the current status of trial NCT01908101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2014-01-08. Estimated completion is 2019-05-04.
What interventions are being tested in trial NCT01908101?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT01908101?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.